iGlarLixi Safe and Effective in Inadequately Controlled T2D

A once-daily injectable therapy of a fixed-ratio combination of insulin glargine and lixisenatide improved glycemic control, with low rates of hypoglycemia, in people with T2D in a real-world setting.

Related Keywords

Qatar ,United States ,American ,Rayaza Malik , ,Qatar Foundation ,Research Division ,American Diabetes ,European Association ,Weill Cornell Medicine Qatar ,Education City ,Diabetes Mellitus Type 2 ,Iabetes Mellitus Type Ii ,Type 2 Diabetes ,Ype 2 Dm ,T2dm ,2d ,Hypoglycemia ,Board Certification ,Boards ,Oard Recertification ,Metabolism ,Etabolic ,Office Visits ,Patient Visits ,Receptors ,Obesity ,Bese ,